[Hormonal contraceptives, peripheral venous insufficiency and the use of a phlebodynamic agent].
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects*; D004341:Drug Evaluation; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use; D006535:Heptaminol / Q000627:therapeutic use; D006801:Humans; D006896:Hydroxyethylrutoside / Q000031:analogs & derivatives / Q000627:therapeutic use; D007434:Intrauterine Devices; D011247:Pregnancy; D011372:Progestins / Q000009:adverse effects; D014689:Venous Insufficiency / Q000139:chemically induced / Q000188:drug therapy*
D000925:Anticoagulants; D003276:Contraceptives, Oral; D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens; D005419:Flavonoids; D006896:Hydroxyethylrutoside; D011372:Progestins; D006535:Heptaminol
Anticoncepción hormonal, insuficiencia venosa periferica y el uso de un flebodinámico